Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus

Abstract

Objective

The anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) may contribute to the pathogenesis of systemic lupus erythematosus. The safety, tolerability, and pharmacodynamics of the selective Bcl-2 inhibitor venetoclax (ABT-199) were assessed in women with systemic lupus erythematosus.

Methods

A phase 1, double-blind, randomized, placebo controlled study evaluated single ascending doses (10, 30, 90, 180, 300, and 500 mg) and multiple ascending doses (2 cycles; 30, 60, 120, 240, 400, and 600 mg for 1 week, and then 3 weeks off per cycle) of orally administered venetoclax. Eligible participants were aged 18–65 years with a diagnosis of systemic lupus erythematosus for 6 months or more receiving stable therapy for systemic lupus erythematosus (which could have included corticosteroids and/or stable antimalarials).

Results

All patients (48/48) completed the single ascending dose, 25 continued into the multiple ascending dose, and 44/50 completed the multiple ascending dose; two of the withdrawals (venetoclax 60 mg and 600 mg cohorts) were due to adverse events. Adverse event incidences were slightly higher in the venetoclax groups compared with the placebo groups, with no dose dependence. There were no serious adverse events with venetoclax. The most common adverse events were headache, nausea, and fatigue. Venetoclax 600 mg multiple ascending dose treatment depleted total lymphocytes and B cells by approximately 50% and 80%, respectively. Naive, switched memory, and memory B-cell subsets enriched in autoreactive B cells exhibited dose-dependent reduction of up to approximately 80%. There were no consistent or marked changes in neutrophils, natural killer cells, hemoglobin, or platelets.

Conclusions

Venetoclax was generally well tolerated in women with systemic lupus erythematosus and reduced total lymphocytes and disease-relevant subsets of antigen-experienced B cells.

Registration

ClinicalTrials.gov: NCT01686555.

Keywords

Systemic lupus erythematosus (SLE)B-lymphocyte T-lymphocyte Bcl-2 clinical trial

Get full access to this article

View all access options for this article.

References

Lisnevskaia

Murphy

Isenberg

. Systemic lupus erythematosus. Lancet 2014; 384: 1878–1888.

Helmick

Felson

Lawrence

et al.

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 15–25.

Liphaus

Kiss

. The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus. Clinics (Sao Paulo) 2010; 65: 327–333.

Ronnblom

Pascual

. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17: 394–399.

Wardemann

Yurasov

Schaefer

et al.

Predominant autoantibody production by early human B cell precursors. Science 2003; 301: 1374–1377.

Yurasov

Tiller

Tsuiji

et al.

Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 2006; 203: 2255–2261.

Yurasov

Wardemann

Hammersen

et al.

Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201: 703–711.

Dorner

Giesecke

Lipsky

. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011; 13: 243.

Chan

Shlomchik

. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160: 51–59.

10.

Chan

Hannum

Haberman

Madaio

Shlomchik

. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639–1648.

11.

Wei

Anolik

Cappione

et al.

A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007; 178: 6624–6633.

12.

Culton

Nicholas

Bunch

et al.

Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J Clin Immunol 2007; 27: 53–68.

13.

Strasser

Whittingham

Vaux

et al.

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661–8665.

14.

Moldoveanu

Follis

Kriwacki

Green

. Many players in BCL-2 family affairs. Trends Biochem Sci 2014; 39: 101–111.

15.

Rose

Latchman

Isenberg

. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. Br J Rheumatol 1997; 36: 158–163.

16.

Venclexta (venetoclax). Full Prescribing Information, North Chicago, IL: AbbVie Inc., 2016.

17.

Grebe

Perper

O'Connor

et al.

Venetoclax (ABT-199), a potent and selective BCL-2 inhibitor, is efficacious in NZB/WF1 mouse model of lupus nephritis and reduces human lymphocyte lifespan in vitro (BA4P.127). J Immunol 2015; 194(suppl 1): 47.7.

18.

Wang

Perper

Schwartz

et al.

ABT-199, a potent and selective BCL-2 inhibitor, prevents lupus nephritis in the spontaneous NZB/W F1 mouse model by depleting selective lymphocyte populations while sparing platelets [abstract]. Arthritis Rheum 2014; 73: 858.

19.

Petri

Buyon

Kim

. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685–691.

20.

Isenberg

Rahman

Allen

et al.

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 902–906.

21.

Minocha

Wong

Zeng

et al.

Pharmacokinetics of the selective B-cell lymphoma-2 (Bcl-2) inhibitor, ABT-199, in female subjects with systemic lupus erythromatosus [abstract]. Arthritis Rheum 2015; 67: 1822.

22.

Khaw

Merino

Anderson

et al.

Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia 2014; 28: 1207–1215.

23.

Mok

Lau

. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–490.

24.

Yaniv

Twig

Shor

et al.

A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev 2015; 14: 75–79.

25.

Guo

Chen

et al.

Anti-endothelin receptor type A autoantibodies in systemic lupus erythematosus-associated pulmonary arterial hypertension. Arthritis Rheum 2015; 67: 2394–2402.

26.

Xiong

Liang

Yang

Zhu

Wang

. The role of angiotensin II type 1 receptor-activating antibodies in patients with lupus nephritis. Int J Clin Pract 2013; 67: 1066–1067.

27.

Cabral-Marques

Riemekasten

. Vascular hypothesis revisited: role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. Autoimmun Rev 2016; 15: 690–694.

28.

Stohl

. Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells. Arthritis Rheum 2015; 67: 612–615.

29.

Zhou

Lian

et al.

Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010; 159: 281–291.

30.

Souers

Leverson

Boghaert

et al.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208.

31.

Roberts

Davids

Pagel

et al.

Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311–322.

32.

Davids

Gerecitano

Potluri

et al.

Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL). J Clin Oncol 2016; 34: abstract 7528.

33.

Merrill

Neuwelt

Wallace

et al.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222–233.

34.

Rovin

Furie

Latinis

et al.

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215–1226.

35.

UCB. UCB announces phase 3 clinical trial program for epratuzumab in systemic lupus erythematosus did not meet primary endpoint. http://www.ucb.com/presscenter/News//article/UCB-announces-Phase-3-clinical-trial-program-for-epratuzumab-in-Systemic-Lupus-Erythematosus-did-not-meet-primary-endpoint-nbsp (accessed 21 September 2016).

36.

Furie

Petri

Zamani

et al.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930.

37.

Navarra

Guzman

Gallacher

et al.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721–731.

38.

Benlysta (belimumab). Full Prescribing Information, Research Triangle Park, NC: GlaxoSmithKline, 2015.

39.

Tipton

Fucile

Darce

et al.

Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol 2015; 16: 755–765.

40.

Nicholas

Dooley

Hogan

et al.

A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol 2008; 126: 189–201.

41.

Blair

Norena

Flores-Borja

et al.

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129–140.

42.

Carrington

Zhang

Sutherland

et al.

Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2015; 112: 4044–4049.

43.

Zhan

Carrington

et al.

Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-alpha production. Arthritis Rheum 2015; 67: 797–808.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB